AXL-selective TKIs have shown promise in preclinical models, particularly in combination with targeted BCR-ABL and FLT3 inhibition in CML and AML, respectively, and clinical trials are currently underway combining AXL inhibition with standard chemotherapy in AML. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.